{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 62,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes two sets of charts: tumor volume over time and survival curves for two different cancer models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/55",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.5,
        "y": 0.25
      },
      "kind": "chart",
      "text": "HCT-116 Xenograft Model: Tumor Volume & Survival Curve after 14 day treatment (7 injections)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae4f63bd-ee30-44a6-94e6-356738ea023d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "MDA-MB-231 Xenograft Model: Tumor Volume after 7 injections",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "daefb03c-4894-4e7a-999e-7cdacc607f2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.5,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Tumor inhibition studies of various micellar formulations. Female nude (NU/NU) mice bearing 250mm3 HCT-116 tumors were treated every 2 d starting at day 0 (7 total tail vein injections, arrows correspond to injection days) at a dose of 4 mg/kg CUR and 0.4 mg/kg DOX.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b570f4f5-fb19-4a90-be86-a323cee4942f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Tumor inhibition studies of various micellar formulations. Nude mice bearing ~150 mm3 MDA-MB-231 tumors were treated every 2 days starting at Day 20 except last injection administered at day 33 (7 total IV injections) at a dose of 6 mg/kg CUR and 1 mg/kg DOX.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4cac4b7-009a-42c2-a7f9-3906b08ea7ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Adapted from: Abouzeid, et. al. Anti-cancer activity of anti-GLUT1 antibody targeted polymeric micelles co-loaded with curcumin and doxorubicin (2013 - https://doi.org/10.3109/1061186x.2013.840639); Abouzeid et al, Nanotechnology-based treatment for chemotherapy-resistant breast cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87952413-cc00-490c-baac-bdb4420c20a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "iMX-111 Preclinical Data in TNBC Breast & Colorectal Cancer: Immix Biopharma Therapies Produce Rare Tumor Shrinkage/Stability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22b365f2-d714-4f35-848c-161925a1551e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3217a417-bc83-4662-8652-aa63eb188831",
      "evidence": "chart/line: HCT-116 Xenograft Model: Tumor Volume & Survival Curve after 14 day treatment (7 injections)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 62,
      "from": 35,
      "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}